Sacral Neuromodulation with the InterStim™ System for Intractable Lower Urinary Tract Dysfunctions (SOUNDS): Results of Clinical Effectiveness, Quality of Life, Patient-Reported Outcomes and Safety in a French Multicenter Observational Study

Irwin, 2006, Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC Study, Eur Urol, 50, 1306, 10.1016/j.eururo.2006.09.019 Milsom, 2002, How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study, BJU Int, 87, 760, 10.1046/j.1464-410x.2001.02228.x Kinsey, 2014, The psychological impact of overactive bladder: a systematic review, J Health Psychol, 21, 69, 10.1177/1359105314522084 Irwin, 2006, Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries, BJU Int, 97, 96, 10.1111/j.1464-410X.2005.05889.x Reeves, 2006, The current and future burden and cost of overactive bladder in five European countries, Eur Urol, 50, 1050, 10.1016/j.eururo.2006.04.018 Hu, 2005, Health-related consequences of overactive bladder: an economic perspective, BJU Int, 96, 43, 10.1111/j.1464-410X.2005.05654.x Lightner, 2019, Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019, J Urol, 202, 558, 10.1097/JU.0000000000000309 Yu, 2005, Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid Program, Value Health, 8, 495, 10.1111/j.1524-4733.2005.00041.x Burkhard, 2018, Urinary Incontinence: EAU Guidelines 2018, European Association of Urology Presented at the EAU Annual Congress Copenhagen 20 2017 Noblett, 2014, Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder, Neurourol Urodyn, 35, 246, 10.1002/nau.22707 Amarenco, 1997, Une échelle spécifique d’évaluation de la perturbation de la qualité de vie au cours des troubles mictionnels: l’échelle Ditrovie, Ann Readapt Med Phys, 40, 21, 10.1016/S0168-6054(97)85882-5 Herdman, 2011, Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L), Qual Life Res, 20, 1727, 10.1007/s11136-011-9903-x Haab, 2008, Comprehensive evaluation of bladder and urethral dysfunction symptoms: development and psychometric validation of the Urinary Symptom Profile (USP) Questionnaire, Urology, 71, 646, 10.1016/j.urology.2007.11.100 Kiresuk, 2014 Jorge, 1993, Etiology and management of fecal incontinence, Dis Colon Rectum, 36, 77, 10.1007/BF02050307 Chartier-Kastler, 2011, Sacral neuromodulation with InterStimTM system: results from the French national register, Prog Urol, 21, 209, 10.1016/j.purol.2010.05.008 Schmidt, 1999, Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group, J Urol, 162, 352, 10.1016/S0022-5347(05)68558-8 Amundsen, 2016, OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women, JAMA, 316, 1366, 10.1001/jama.2016.14617 Spinelli, 2001, Chronic sacral neuromodulation in patients with lower urinary tract symptoms: results from a national register, J Urol, 166, 541, 10.1016/S0022-5347(05)65979-4 Chartier-Kastler E, Ruffion A, Le Normand, et al. Sacral neuromodulation with the InterStim™ system for intractable urinary voiding dysfunction (SOUNDS): responder rates in a real-world French patient collective: submitted to EAU conference (to appear in European Urology Supplements). McClure, 2017, Instrument-defined estimates of the minimally important difference for EQ-5D-5L Index scores, Value Health, 20, 644, 10.1016/j.jval.2016.11.015 Haywood, 2008, EuroQol EQ-5D and condition-specific measures of health outcome in women with urinary incontinence: reliability, validity and responsiveness, Qual Life Res, 17, 475, 10.1007/s11136-008-9311-z Davis, 2013, A review of the psychometric performance of the EQ-5D in people with urinary incontinence, Health Qual Life Outcomes., 11, 20, 10.1186/1477-7525-11-20 Hassouna, 2000, Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety, J Urol, 163, 1849, 10.1016/S0022-5347(05)67558-1 van Kerrebroeck, 2007, Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study, J Urol, 178, 2029, 10.1016/j.juro.2007.07.032 Siddiqui, 2010, Efficacy and adverse events of sacral nerve stimulation for overactive bladder: a systematic review, Neurourol Urodyn, 29, S18, 10.1002/nau.20786 Scheepens, 2001, Buttock placement of the implantable pulse generator: a new implantation technique for sacral neuromodulation – a multicenter study, Eur Urol, 40, 434, 10.1159/000049812 Noblett, 2016, Detailed analysis of adverse events and surgical interventions in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients, Neurourol Urodyn., 36, 1136, 10.1002/nau.23076 Matzel, 2017, Sacral neuromodulation: standardized electrode placement technique, Neuromodulation, 20, 816, 10.1111/ner.12695